🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with data suggesting over 82 million new cases annually. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

According to findings released by a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which involves a dual-drug approach. The study involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals directly involved have expressed positive views. Access to a single-dose, oral treatment such as this is described as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.